Apellis Pharmaceuticals Inc (APLS.OQ)
APLS.OQ on NASDAQ Stock Exchange Global Select Market
24.52USD
9:00pm BST
24.52USD
9:00pm BST
Change (% chg)
$0.31 (+1.28%)
$0.31 (+1.28%)
Prev Close
$24.21
$24.21
Open
$24.35
$24.35
Day's High
$24.69
$24.69
Day's Low
$24.05
$24.05
Volume
115,121
115,121
Avg. Vol
61,829
61,829
52-wk High
$31.69
$31.69
52-wk Low
$12.51
$12.51
Revenue & Earnings Per Share
Revenue* | Earnings Per Share** | ||
---|---|---|---|
FY 2017 | Dec '17 | 0.00 | -0.371 |
Sep '17 | 0.00 | -0.235 | |
Jun '17 | |||
FY 2016 | Dec '16 | 0.00 | -0.134 |
Sep '16 | 0.00 | -0.146 | |
Jun '16 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
# of Estimates | Mean | High | Low | 1 Year Ago | |
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
Quarter Ending Sep-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
Year Ending Dec-18 | 2 | 0.00 | 0.00 | 0.00 | -- |
Year Ending Dec-19 | 2 | 0.00 | 0.00 | 0.00 | -- |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 2 | -0.35 | -0.30 | -0.40 | -- |
Quarter Ending Sep-18 | 2 | -0.37 | -0.33 | -0.41 | -- |
Year Ending Dec-18 | 3 | -1.31 | -1.06 | -1.62 | -- |
Year Ending Dec-19 | 3 | -1.54 | -1.18 | -1.73 | -- |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
Company | industry | sector | ||
---|---|---|---|---|
P/E Ratio (TTM) | -- | 30.95 | 32.74 | |
P/E High - Last 5 Yrs. | -- | 40.70 | 45.72 | |
P/E Low - Last 5 Yrs. | -- | 23.63 | 24.22 | |
Beta | -- | 0.89 | 0.88 | |
Price to Sales (TTM) | -- | 3.94 | 5.71 | |
Price to Book (MRQ) | -- | 4.80 | 5.37 | |
Price to Tangible Book (MRQ) | -- | 5.61 | 6.95 | |
Price to Cash Flow (TTM) | -- | 22.91 | 23.32 | |
% Owned Institutions | -- | 1.21 | 2.17 |
Dividends
Company | industry | sector | ||
---|---|---|---|---|
Dividend Yield | -- | 1.56 | 1.50 | |
Dividend Yield - 5 Year Avg | -- | 1.57 | 1.51 | |
Dividend 5 Year Growth Rate | -- | 4.47 | 5.32 | |
Payout Ratio(TTM) | -- | 45.35 | 43.29 |
Growth Rates
Company | industry | sector | ||
---|---|---|---|---|
Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 3.69 | 9.21 | |
Sales (TTM) vs TTM 1 Yr. Ago | -- | 4.83 | 5.69 | |
Sales - 5 Yr. Growth Rate | -- | 10.08 | 10.32 | |
EPS (MRQ) vs Qtr. 1 Yr. Ago | -- | 16.36 | 19.36 | |
EPS (TTM) vs TTM 1 Yr. Ago | -- | -- | -- | |
EPS - 5 Yr. Growth Rate | -- | 9.87 | 10.76 | |
Capital Spending - 5 Yr. Growth Rate | -- | 15.52 | 15.47 |
Financial Strength
Company | industry | sector | |
---|---|---|---|
Quick Ratio (MRQ) | -- | 2.12 | 2.19 |
Current Ratio (MRQ) | -- | 2.90 | 2.98 |
LT Debt to Equity (MRQ) | -- | 9.88 | 12.18 |
Total Debt to Equity (MRQ) | -- | 13.86 | 16.45 |
Interest Coverage (TTM) | -- | 35.89 | 32.81 |
Profitability Ratios
Company | industry | sector | ||
---|---|---|---|---|
Gross Margin (TTM) | -- | 54.81 | 54.44 | |
Gross Margin - 5 Yr. Avg. | -- | 52.15 | 52.20 | |
EBITD Margin (TTM) | -- | -- | -- | |
EBITD - 5 Yr. Avg | -- | 18.57 | 10.96 | |
Operating Margin (TTM) | -- | 14.36 | 4.73 | |
Operating Margin - 5 Yr. Avg. | -- | 14.52 | 6.40 | |
Pre-Tax Margin (TTM) | -- | 14.82 | 5.57 | |
Pre-Tax Margin - 5 Yr. Avg. | -- | 14.90 | 6.81 | |
Net Profit Margin (TTM) | -- | 11.08 | 1.87 | |
Net Profit Margin - 5 Yr. Avg. | -- | 11.20 | 3.09 | |
Effective Tax Rate (TTM) | -- | 23.16 | 23.04 | |
Effective Tax Rate - 5 Yr. Avg. | -- | 23.42 | 23.96 |
Efficiency
Company | industry | sector | ||
---|---|---|---|---|
Revenue/Employee (TTM) | -- | 938,079,949 | 846,830,978 | |
Net Income/Employee (TTM) | -- | 110,368,367 | 99,616,195 | |
Receivable Turnover (TTM) | -- | 5.63 | 5.78 | |
Inventory Turnover (TTM) | -- | 2.59 | 3.35 | |
Asset Turnover (TTM) | -- | 0.95 | 0.92 |
Management Effectiveness
Company | industry | sector | ||
---|---|---|---|---|
Return on Assets (TTM) | -- | 11.40 | 10.95 | |
Return on Assets - 5 Yr. Avg. | -- | 12.91 | 12.31 | |
Return on Investment (TTM) | -- | 14.84 | 14.38 | |
Return on Investment - 5 Yr. Avg. | -- | 16.88 | 16.10 | |
Return on Equity (TTM) | -- | 16.34 | 16.07 | |
Return on Equity - 5 Yr. Avg. | -- | 17.98 | 17.39 |
Note: Units in Millions of US Dollars
Performance for Apellis Pharmaceuticals Inc
Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
---|---|---|---|---|
4 Week | -- | -- | -- | 23 |
13 Week | -- | -- | -- | 34 |
26 Week | -- | -- | -- | 29 |
52 Week | -- | -- | -- | 12 |
YTD | -- | -- | -- | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Apellis Pharmaceuticals Announces Pricing Of Offering Of Common Stock
- BRIEF-Apellis Pharmaceuticals Announces Proposed Offering Of Common Stock
- BRIEF-Apellis Pharmaceuticals Files For Offering Of 5 Million Shares Of Common Stock
- BRIEF-Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab
- BRIEF-Apellis Pharmaceuticals Q4 Loss Per Share $0.61
Institutional Holders
% Shares Owned: | 31.69% |
# of Holders: | 67 |
Total Shares Held: | 15,962,717 |
3 Mo. Net Change: | 12,883 |
# New Positions: | 3 |
# Closed Positions: | 0 |
# Increased Positions: | 5 |
# Reduced Positions: | 5 |
# Net Buyers: | 0 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.